In our cohorts, 55% of the cases were positive for PD-L1 (≥1% positive tumor cells), which is in line with other large real-world studies with patients exclusively or mainly from Europe and North America containing a prevalence of 52–63% [12,16,17,18]. The gene discussed is CD274; the disease is neoplasm.